Arch Therapeutics is a medical device company developing a
novel approach to stopping bleeding and controlling leaking during surgery and
trauma care. The company’s leading product candidate, the AC5 Surgical
Hemostatic Device™, is being designed to achieve hemostasis in minimally
invasive and open surgical procedures, effectively making surgery faster and
safer for patients. Unlike currently available products, AC5 has been shown to
promptly stop bleeding by conforming to irregular wound geometry, and, with a
completely transparent construction, it allows surgeons to maintain a clear
field of vision directly into a wound without hampering future healing.
In recent months, Arch has made considerable progress in the
development of its promising hemostatic device. In April, the company announced
the results of a study designed to compare the effectiveness of AC5 against
currently marketed hemostats. Arch’s device demonstrated an average time to
hemostasis of significantly less than 30 seconds, while the
commercially-available gelatin-thrombin hemostat took an average of more than
200 percent longer. In June, the company built on these results when it received
favorable data from a preclinical toxicity test indicating that AC5 was
well-tolerated among test subjects.
“These results present another snapshot of promising data
for AC5,” Dr. Terrence Norchi, president and chief executive officer of Arch,
stated in a news release. “We are continuing to study the characteristics,
safety and performance of AC5 in preclinical studies as we prepare to start our
human clinical trial next quarter.”
In an effort to fund its upcoming clinical studies, Arch
recently completed a private placement that is expected to provide more than $3
million of additional capital after related expenses. With this added
flexibility, the company will look to continue marching toward the eventual
commercialization of AC5 following the completion of its impending human
trials.
When commercialized, AC5 will give Arch improved access to
the rapidly growth market for minimally invasive surgery (MIS). According to a
report by Photonics, the global market for MIS is expected to reach $50.6 billion
by 2019, up from just $25 billion in 2012. AC5 is ideal for this market because
of it leaves no sticky or glue-like residue, enabling for improved precision
during both MIS and open surgical procedures, as well as faster recovery times
for patients.
Moving forward, Arch will continue toward the future
commercialization of its innovative device. For prospective shareholders, this
progress, along with the vast commercial potential of AC5 in a selection of
thriving medical markets, makes the company an intriguing investment
opportunity in the months to come.
For more information, visit www.archtherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment